Patents by Inventor Weikang Tao

Weikang Tao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250099596
    Abstract: The present disclosure relates to a tetrahydronaphthalene compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a tetrahydronaphthalene compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a therapeutic agent, in particular the use thereof as an estrogen receptor degrader, the use in the preparation of a drug for treating and/or preventing estrogen receptor-mediated or dependent diseases or conditions and the use in the preparation of a drug for treating and/or preventing diseases or conditions by means of degrading a target protein.
    Type: Application
    Filed: March 29, 2022
    Publication date: March 27, 2025
    Inventors: Fanglong Yang, Nan Yu, Zhiwei Liu, Feng He, Weikang Tao
  • Patent number: 12258394
    Abstract: Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: March 25, 2025
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Hua Ying, Jinping Shi, Yifang Wang, Qiyue Hu, Hu Ge, Weikang Tao
  • Patent number: 12258405
    Abstract: The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi-specific antibody.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: March 25, 2025
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Hua Ying, Ling Zhang, Xiaoying Yang, Hu Ge, Weikang Tao
  • Publication number: 20250057968
    Abstract: An anti-DLL3 antibody and a pharmaceutical use thereof, and an antibody-drug conjugate containing the anti-DLL3 antibody. The present disclosure relates to an anti-DLL3 antibody-ecteinascidin drug conjugate represented by general formula (Pc-L-D), wherein Pc is the anti-DLL3 antibody.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 20, 2025
    Inventors: Xin Ye, Qingqing Yao, Xinsheng Jin, Hua Ying, Weikang Tao
  • Patent number: 12227499
    Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: February 18, 2025
    Assignee: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Liangliang Zheng, Feng He, Weikang Tao
  • Publication number: 20250043022
    Abstract: Provided are an antigen-binding molecule specifically binding to PSMA and CD3, and a pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.
    Type: Application
    Filed: February 7, 2023
    Publication date: February 6, 2025
    Inventors: Hua YING, Jinping SHI, Hao YANG, Xiaomin ZHANG, Xinsheng JIN, Weikang TAO
  • Patent number: 12215103
    Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.
    Type: Grant
    Filed: March 21, 2024
    Date of Patent: February 4, 2025
    Assignee: Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Liangliang Zheng, Feng He, Weikang Tao
  • Patent number: 12202891
    Abstract: Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a medicament for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: January 21, 2025
    Inventors: Jinping Shi, Hua Ying, Tingting Li, Yifang Wang, Guimei Yang, Hu Ge, Weikang Tao
  • Patent number: 12187684
    Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: January 7, 2025
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Yinfa Yan, Minsheng Zhang, Dong Liu, Fengqi Zhang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • Publication number: 20250000989
    Abstract: The present disclosure relates to a pyrrolo benzodiazepine derivative and a conjugate, preparation method and use thereof. In particular, the present disclosure relates to a compound of formula (DL) and a antibody-drug conjugate thereof, a pharmaceutical composition containing same, and a use thereof in the preparation of a medicament for the treatment of cancer. The definitions of groups in the general formula (DL) are as defined in the description.
    Type: Application
    Filed: September 30, 2022
    Publication date: January 2, 2025
    Inventors: Jianyan XU, Xiaofeng CAI, Bolei QU, Ying ZHANG, Xiaoxi CHEN, Feng HE, Weikang TAO, Lingjian ZHU, Min HONG, Jian HUANG, Yanbing LI, Xiaolang XU, Zhipeng HU, Zhouyang XUE, Lingfeng YOU
  • Patent number: 12162879
    Abstract: Disclosed are a pyridopyrimidine derivative as shown in general formula (I), a preparation method therefor and a pharmaceutical composition containing the derivative, and the use thereof as a therapeutic agent, particularly as a TLR8 agonist, wherein each substituent of general formula (I) is the same as those defined in the description.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: December 10, 2024
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Guobao Zhang, Yiqian Chen, Feng He, Weikang Tao
  • Publication number: 20240400670
    Abstract: An anti-IL23 antibody fusion protein and uses thereof, the anti-IL23 antibody fusion protein containing anti IL23 antibodies and TAC polypeptides, and the IL23 antibodies specifically binding the human IL23 p19 subunit. The anti-IL23 antibody fusion protein can be used for the treatment or improvement of B cell disorders or autoimmune diseases.
    Type: Application
    Filed: September 30, 2022
    Publication date: December 5, 2024
    Inventors: Langyong MAO, Hua YING, Yi XUE, Xinsheng JIN, Weikang TAO
  • Publication number: 20240392020
    Abstract: Provided is an antigen-binding molecule, particularly a domain-engineered antibody, wherein at least one constant region domain CH1/CL of the antibody is replaced by a Titin T-chain/Obscurin-O chain.
    Type: Application
    Filed: May 12, 2022
    Publication date: November 28, 2024
    Inventors: Hua Ying, Qiyue Hu, Xinsheng Jin, Jinping Shi, Ling Zhang, Langyong Mao, Xin Ye, Weikang Tao
  • Publication number: 20240360133
    Abstract: The present invention relates to a fused tricyclic compound, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a fused tricyclic compound represented by general formula (1), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, particularly a use as a TLR7/8/9 inhibitor and a use in preparing a drug for the treatment and/or prevention of inflammatory and autoimmune diseases. The definition of each group in general formula (1) is as defined in the description.
    Type: Application
    Filed: November 26, 2021
    Publication date: October 31, 2024
    Inventors: Xiaomin Zhang, Weimin Hu, Feng He, Weikang Tao
  • Publication number: 20240352132
    Abstract: An antigen-binding molecule specifically binding to HGFR and EGFR, and the pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.
    Type: Application
    Filed: July 14, 2022
    Publication date: October 24, 2024
    Inventors: Xin YE, Le SUN, Weiwei ZHANG, Weikang TAO
  • Publication number: 20240327388
    Abstract: The present invention relates to a quinolinamine compound, a preparation method therefor and an application thereof in pharmaceuticals. Specifically, the present invention relates to a quinolinamine compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a therapeutic agent, especially use thereof as a miRNA regulator and use thereof in preparation of a drug for treating diseases or conditions that can be improved by regulating miRNA levels.
    Type: Application
    Filed: May 27, 2022
    Publication date: October 3, 2024
    Inventors: Fanglong YANG, Minqiang JIA, Huanyu TANG, Yonglei QUE, Feng HE, Weikang TAO
  • Publication number: 20240327434
    Abstract: The present disclosure relates to a fused tetracyclic compound, a preparation method therefor and an application thereof in medicine. Specifically, the present disclosure relates to a fused tetracyclic compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a therapeutic agent, in particular use thereof in preparation of drugs for inhibiting KRAS G12D. The groups in general formula (I) are as defined in the description.
    Type: Application
    Filed: June 21, 2022
    Publication date: October 3, 2024
    Inventors: Xin LI, Feng SHEN, Huaide DONG, Yang CHEN, Feng HE, Weikang TAO
  • Publication number: 20240301031
    Abstract: The present application relates to a truncated TACI polypeptide and a fusion protein and use thereof. Specifically, provided are a TACI polypeptide as shown in SEQ ID NO: 8, a truncated fragment thereof, a mutation sequence thereof, and a fusion protein comprising the TACI polypeptide and use thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: September 12, 2024
    Inventors: Langyong MAO, Hua YING, Xinsheng JIN, Lingling LI, Weikang TAO
  • Publication number: 20240287094
    Abstract: A nitrogen-containing heterocyclic compound, a preparation method therefor, and an application thereof in medicines. Specifically, the present disclosure relates to a nitrogen-containing heterocyclic compound as represented by general formula (IM), a preparation method therefor, a pharmaceutical composition comprising the compound, a use of the pharmaceutical composition serving as a therapeutic agent, in particular as a PARP1 inhibitor, and a use of the pharmaceutical composition in the preparation of a drug for treating and/or preventing cancer.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 29, 2024
    Inventors: Xin LI, Huaide DONG, Guodong CAI, Feng HE, Weikang TAO
  • Publication number: 20240269307
    Abstract: Provided are an anti-Nectin-4 antibody and an anti-Nectin-4 antibody-drug conjugate, and a medicinal user thereof. The anti-Nectin-4 antibody, and the anti-Nectin-4 antibody-drug conjugate as represented by general formula (Pc-L-Y-D) are involved, wherein Pc is the anti-Nectin-4 antibody, and L, Y, and n are as defined in the description.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 15, 2024
    Inventors: Yang YANG, Haoying ZHANG, Weikang TAO